# Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

> **NCT03833141** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 170 (actual)

## Conditions studied

- Severe Eosinophilic Asthma

## Interventions

- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT03833141
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833141, "Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03833141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*